ABOS Stock Analysis: Buy, Sell, or Hold?
ABOS - Acumen Pharmaceuticals, Inc. Common Stock
$2.19
-0.06 (-2.67%)
▼
5d:
-17.05%
30d:
-2.67%
90d:
-22.34%
WAIT
LOW Confidence
Analysis Updated: Jul 20, 2026 12:00 AM ET
Earnings: Aug 11, 2026
21d
Get Alerted When ABOS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ABOS is down 17.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ABOS is down 17.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ABOS is currently trading at $2.19, which is considered slightly low relative to its 30-day fair value range of $2.26 to $2.64.
Technical Outlook: Technically, ABOS is in a strong downtrend. Immediate support is located at $2.09, while resistance sits at $2.78.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.40 (+228.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ABOS is in a strong downtrend. Immediate support is located at $2.09, while resistance sits at $2.78.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.40 (+228.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.26 -
$2.64
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 228.9% below Wall St target ($7.40)
- WARNING: Recommendation downgraded due to -17.0% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$2.26 -
$2.64
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$2.09
Resistance Level
$2.78
Current Trend
Strong Downtrend
Technical data as of
Jul 17, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.49
Wall Street Target
$7.40
(+228.9%)
Share & Embed Analysis
Last updated: July 20, 2026 1:54 PM ET
Data refreshes hourly during market hours. Next update: 2:54 PM
Data refreshes hourly during market hours. Next update: 2:54 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABOS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Eric Siemers
SELL
895 shares
2026-01-22
Matt Zuga
SELL
1687 shares
2026-01-22
Russell Barton
SELL
462 shares
2026-01-22
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 52 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1054 | 55 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$56 | 48 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$125 | 60 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
